Literature DB >> 28877877

Acute blood loss stimulates fibroblast growth factor 23 production.

Seham Rabadi1, Ikemesit Udo1, David E Leaf2, Sushrut S Waikar2, Marta Christov1.   

Abstract

Fibroblast growth factor 23 (FGF23) production is upregulated by iron deficiency and hypoxia. However, the influence of acute blood loss, and the resulting increases in circulating erythropoietin, on FGF23 production is unknown. Using wild-type C57BL/6 mice, we show that acute loss of 10% total blood volume leads to an increase in plasma C-terminal FGF23 (cFGF23) levels within 6 h, while plasma levels of intact FGF23, phosphate, calcium, parathyroid hormone, iron, and ferritin remain similar to control mice without acute blood loss. Volume resuscitation with PBS did not significantly alter these findings. The increase in plasma cFGF23 levels in bled animals was accompanied by increased plasma erythropoietin levels at 6 h. Administration of erythropoietin led to an acute increase in plasma cFGF23 levels similar to that observed in acute blood loss. Fgf23 mRNA expression was increased 20-fold in bone marrow, but not in bone, of bled vs. control mice, suggesting bone marrow as a key source of elevated plasma FGF23 levels following acute blood loss. To extend these findings to humans, we measured plasma cFGF23 levels in 131 critically ill patients admitted to the intensive care unit. In univariate and multivariate models, we found a positive association between number of red blood cell transfusions, an indirect indicator of acute blood loss, and plasma cFGF23 levels. We conclude that FGF23 production is rapidly increased after acute blood loss and that erythropoietin may be the mediator of this increase. Thus erythropoietin may represent a novel physiological regulator of FGF23 production.

Entities:  

Keywords:  FGF23; anemia; bleeding; erythropoietin; iron

Mesh:

Substances:

Year:  2017        PMID: 28877877      PMCID: PMC5866351          DOI: 10.1152/ajprenal.00081.2017

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  30 in total

1.  The human response to acute enteral and parenteral phosphate loads.

Authors:  Roberto Scanni; Matthias vonRotz; Sigrid Jehle; Henry N Hulter; Reto Krapf
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

2.  Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

Authors:  Erik A Imel; Munro Peacock; Amie K Gray; Leah R Padgett; Siu L Hui; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2011-08-31       Impact factor: 5.958

3.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Authors:  Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  JAMA       Date:  2011-06-15       Impact factor: 56.272

4.  Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery.

Authors:  David E Leaf; Marta Christov; Harald Jüppner; Edward Siew; T Alp Ikizler; Aihua Bian; Guanhua Chen; Venkata S Sabbisetti; Joseph V Bonventre; Xuan Cai; Myles Wolf; Sushrut S Waikar
Journal:  Kidney Int       Date:  2016-02-17       Impact factor: 10.612

5.  FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis.

Authors:  Lindsay M Coe; Sangeetha Vadakke Madathil; Carla Casu; Beate Lanske; Stefano Rivella; Despina Sitara
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

Review 6.  Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.

Authors:  Myles Wolf; Kenneth E White
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-07       Impact factor: 2.894

7.  Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

Authors:  Myles Wolf; Todd A Koch; David B Bregman
Journal:  J Bone Miner Res       Date:  2013-08       Impact factor: 6.741

8.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

9.  Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.

Authors:  Fenna van Breda; Mireille E Emans; Karien van der Putten; Branko Braam; Frans J van Ittersum; Rob J Kraaijenhagen; Martin H de Borst; Marc Vervloet; Carlo A J M Gaillard
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

10.  Osteocyte-specific deletion of Fgfr1 suppresses FGF23.

Authors:  Zhousheng Xiao; Jinsong Huang; Li Cao; Yingjuan Liang; Xiaobin Han; Leigh Darryl Quarles
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

View more
  27 in total

Review 1.  Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease.

Authors:  Jodie L Babitt; Despina Sitara
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

Review 2.  Hypoxia Signaling in the Skeleton: Implications for Bone Health.

Authors:  Clare E Yellowley; Damian C Genetos
Journal:  Curr Osteoporos Rep       Date:  2019-02       Impact factor: 5.096

Review 3.  Non-renal-Related Mechanisms of FGF23 Pathophysiology.

Authors:  Mark R Hanudel; Marciana Laster; Isidro B Salusky
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

4.  Selective pharmacological inhibition of the sodium-dependent phosphate cotransporter NPT2a promotes phosphate excretion.

Authors:  Valerie Clerin; Hiroshi Saito; Kevin J Filipski; An Hai Nguyen; Jeonifer Garren; Janka Kisucka; Monica Reyes; Harald Jüppner
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

5.  Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.

Authors:  Mark R Hanudel; Michele F Eisenga; Maxime Rappaport; Kristine Chua; Bo Qiao; Grace Jung; Victoria Gabayan; Barbara Gales; Georgina Ramos; Maarten A de Jong; Jelmer J van Zanden; Martin H de Borst; Stephan J L Bakker; Elizabeta Nemeth; Isidro B Salusky; Carlo A J M Gaillard; Tomas Ganz
Journal:  Nephrol Dial Transplant       Date:  2019-12-01       Impact factor: 5.992

6.  Extra-Large Gα Protein (XLαs) Deficiency Causes Severe Adenine-Induced Renal Injury with Massive FGF23 Elevation.

Authors:  Julia Matthias; Qiuxia Cui; Lauren T Shumate; Antonius Plagge; Qing He; Murat Bastepe
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

7.  Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.

Authors:  Connor Francis; Guillaume Courbon; Claire Gerber; Samantha Neuburg; Xueyan Wang; Corey Dussold; Maralee Capella; Lixin Qi; Tamara Isakova; Rupal Mehta; Aline Martin; Myles Wolf; Valentin David
Journal:  Kidney Int       Date:  2019-08-30       Impact factor: 10.612

8.  Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men.

Authors:  Arezoo Daryadel; Carla Bettoni; Thomas Haider; Pedro H Imenez Silva; Udo Schnitzbauer; Eva Maria Pastor-Arroyo; Roland H Wenger; Max Gassmann; Carsten A Wagner
Journal:  Pflugers Arch       Date:  2018-07-02       Impact factor: 3.657

9.  FGF23 Synthesis and Activity.

Authors:  Megan L Noonan; Kenneth E White
Journal:  Curr Mol Biol Rep       Date:  2019-01-17

10.  Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF.

Authors:  Jonathan A Wheeler; Erica L Clinkenbeard
Journal:  Curr Mol Biol Rep       Date:  2019-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.